Fosfomycin: Resurgence of an old companion

Journal of Infection and Chemotherapy

Volumn 22, Issue 5, 2016, Pages 273-280

  Sastry, Sangeeta ^a,b   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Clinical outcome; Combination therapy; Extensive drug resistance (XDR); Multidrug resistance (MDR); Pharmacokinetics; Susceptibility testing

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; FOSFOMYCIN; MEROPENEM; METOCLOPRAMIDE; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACUTE UNCOMPLICATED URINARY TRACT INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENSIVE DRUG RESISTANCE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPOKALEMIA; IN VITRO STUDY; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84959244092     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2016.01.010     Document Type: Review

References (118)

1. Bouchillon S.K., Badal R.E., Hoban D.J., Hawser S.P. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther 2013, 35:872-877.
2. Bradford P.A. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14:933-951.
3. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
4. Rodriguez-Bano J., Alcala J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
5. Doi Y., Park Y.S., Rivera J.I., Adams-Haduch J.M., Hingwe A., Sordillo E.M., et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013, 56:641-648.
6. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002, 113:5S-13S.
7. Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:e103-e120.
8. Hendlin D., Stapley E.O., Jackson M., Wallick H., Miller A.K., Wolf F.J., et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969, 166:122-123.
9. Kahan F.M., Kahan J.S., Cassidy P.J., Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N. Y Acad Sci 1974, 235:364-386.
10. Silhavy T.J., Hartig-Beecken I., Boos W. Periplasmic protein related to the sn-glycerol-3-phosphate transport system of Escherichia coli. J Bacteriol 1976, 126:951-958.
11. Kadner R.J., Winkler H.H. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol 1973, 113:895-900.
12. Takahata S., Ida T., Hiraishi T., Sakakibara S., Maebashi K., Terada S., et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2010, 35:333-337.
13. Kim D.H., Lees W.J., Kempsell K.E., Lane W.S., Duncan K., Walsh C.T. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry 1996, 35:4923-4928.
14. Venkateswaran P.S., Wu H.C. Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12. J Bacteriol 1972, 110:935-944.
15. Horii T., Kimura T., Sato K., Shibayama K., Ohta M. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother 1999, 43:789-793.
16. Arca P., Rico M., Brana A.F., Villar C.J., Hardisson C., Suarez J.E. Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother 1988, 32:1552-1556.
17. Arca P., Reguera G., Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997, 40:393-399.
18. Bernat B.A., Laughlin L.T., Armstrong R.N. Fosfomycin resistance protein (FosA) is a manganese metalloglutathione transferase related to glyoxalase I and the extradiol dioxygenases. Biochemistry 1997, 36:3050-3055.
19. Roberts A.A., Sharma S.V., Strankman A.W., Duran S.R., Rawat M., Hamilton C.J. Mechanistic studies of FosB: a divalent-metal-dependent bacillithiol-S-transferase that mediates fosfomycin resistance in Staphylococcus aureus. Biochem J 2013, 451:69-79.
20. Fillgrove K.L., Pakhomova S., Newcomer M.E., Armstrong R.N. Mechanistic diversity of fosfomycin resistance in pathogenic microorganisms. J Am Chem Soc 2003, 125:15730-15731.
21. Garcia P., Arca P., Evaristo Suarez J. Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrob Agents Chemother 1995, 39:1569-1573.
22. Wachino J., Yamane K., Suzuki S., Kimura K., Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 2010, 54:3061-3064.
23. Lee S.Y., Park Y.J., Yu J.K., Jung S., Kim Y., Jeong S.H., et al. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. J Antimicrob Chemother 2012, 67:2843-2847.
24. Hou J., Huang X., Deng Y., He L., Yang T., Zeng Z., et al. Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother 2012, 56:2135-2138.
25. Hou J., Yang X., Zeng Z., Lv L., Yang T., Lin D., et al. Detection of the plasmid-encoded fosfomycin resistance gene fosA3 in Escherichia coli of food-animal origin. J Antimicrob Chemother 2013, 68:766-770.
26. Ho P.L., Chan J., Lo W.U., Law P.Y., Li Z., Lai E.L., et al. Dissemination of plasmid-mediated fosfomycin resistance fosA3 among multidrug-resistant Escherichia coli from livestock and other animals. J Appl Microbiol 2013, 114:695-702.
27. Ho P.L., Chan J., Lo W.U., Lai E.L., Cheung Y.Y., Lau T.C., et al. Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J Med Microbiol 2013, 62:1707-1713.
28. CTX-M-55/-14/-65 in Escherichia coli from chickens in China. Front Microbiol 2014, 5:688.
29. Jiang Y., Shen P., Wei Z., Liu L., He F., Shi K., et al. Dissemination of a clone carrying a fosA3-harbouring plasmid mediates high fosfomycin resistance rate of KPC-producing Klebsiella pneumoniae in China. Int J Antimicrob Agents 2015, 45:66-70.
30. Chen C., Xu X., Qu T., Yu Y., Ying C., Liu Q., et al. Prevalence of the fosfomycin-resistance determinant, fosB3, in Enterococcus faecium clinical isolates from China. J Med Microbiol 2014, 63:1484-1489.
31. Xu X., Chen C., Lin D., Guo Q., Hu F., Zhu D., et al. The fosfomycin resistance gene fosB3 is located on a transferable, extrachromosomal circular intermediate in clinical Enterococcus faecium isolates. PLoS One 2013, 8:e78106.
32. Etienne J., Gerbaud G., Fleurette J., Courvalin P. Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol Lett 1991, 68:119-122.
33. Takeuchi F., Watanabe S., Baba T., Yuzawa H., Ito T., Morimoto Y., et al. Whole-genome sequencing of Staphylococcus haemolyticus uncovers the extreme plasticity of its genome and the evolution of human-colonizing staphylococcal species. J Bacteriol 2005, 187:7292-7308.
34. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement 2015, Wayne, PA.
35. Barry A.L., Fuchs P.C. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob Agents Chemother 1991, 35:1235-1238.
36. Hirsch E.B., Raux B.R., Zucchi P.C., Kim Y., McCoy C., Kirby J.E., et al. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. Int J Antimicrob Agents 2015.
37. Perdigao-Neto L.V., Oliveira M.S., Rizek C.F., Carrilho C.M., Costa S.F., Levin A.S. Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods. Antimicrob Agents Chemother 2014, 58:1763-1767.
38. Kaase M., Szabados F., Anders A., Gatermann S.G. Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany. J Clin Microbiol 2014, 52:1893-1897.
39. Diez-Aguilar M., Morosini M.I., del Campo R., Garcia-Castillo M., Zamora J., Canton R. In vitro activity of fosfomycin against a collection of clinical Pseudomonas aeruginosa isolates from 16 Spanish hospitals: establishing the validity of standard broth microdilution as susceptibility testing method. Antimicrob Agents Chemother 2013, 57:5701-5703.
40. Lu C.L., Liu C.Y., Huang Y.T., Liao C.H., Teng L.J., Turnidge J.D., et al. Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob Agents Chemother 2011, 55:4295-4301.
41. Falagas M.E., Maraki S., Karageorgopoulos D.E., Kastoris A.C., Kapaskelis A., Samonis G. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents 2010, 35:497-499.
42. Pogue J.M., Marchaim D., Abreu-Lanfranco O., Sunkara B., Mynatt R.P., Zhao J.J., et al. Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008-10. J Antibiot (Tokyo) 2013, 66:625-627.
43. Neuner E.A., Sekeres J., Hall G.S., van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012, 56:5744-5748.
44. Demir T., Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013, 17:e966-e970.
45. Naber K.G., Schito G., Botto H., Palou J., Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy. Eur Urol 2008, 54:1164-1175.
46. Biondo C.M., Rocha J.L., Tuon F.F. Fosfomycin in vitro resistance of Escherichia coli from the community. Braz J Infect Dis 2011, 15:96.
47. Karlowsky J.A., Denisuik A.J., Lagace-Wiens P.R., Adam H.J., Baxter M.R., Hoban D.J., et al. In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study. Antimicrob Agents Chemother 2014, 58:1252-1256.
48. Gobernado M., Valdes L., Alos J.I., Garcia-Rey C., Dal-Re R., Garcia-de-Lomas J., et al. Antimicrobial susceptibility of clinical Escherichia coli isolates from uncomplicated cystitis in women over a 1-year period in Spain. Rev Esp Quimioter 2007, 20:68-76.
49. Maraki S., Samonis G., Rafailidis P.I., Vouloumanou E.K., Mavromanolakis E., Falagas M.E. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009, 53:4508-4510.
50. Johnson J.R., Drawz S.M., Porter S., Kuskowski M.A. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob Agents Chemother 2013, 57:4856-4860.
51. Hutley E.J., Chand M.A., Hounsome G., Kelsey M.C. Fosfomycin: an oral agent for urinary infection caused by extended spectrum β-lactamase producing organisms. J Infect 2010, 60:308-309.
52. Liu H.Y., Lin H.C., Lin Y.C., Yu S.H., Wu W.H., Lee Y.J. Antimicrobial susceptibilities of urinary extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011, 44:364-368.
53. Araj G.F., Jaber F.A. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. J Med Liban 2012, 60:142-147.
54. Saltoglu N., Karali R., Yemisen M., Ozaras R., Balkan, Mete B., et al. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum β-lactamase-producing Escherichia coli and antimicrobial activities. Int J Clin Pract 2015, 69:766-770.
55. Keating G.M. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs 2013, 73:1951-1966.
56. Oteo J., Bautista V., Lara N., Cuevas O., Arroyo M., Fernández S., et al. Spanish ESBL-EARS-Net Study Group. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother. 2010, 65:2459-2463.
57. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
58. KPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010, 54:526-529.
59. Alexander B.T., Marschall J., Tibbetts R.J., Neuner E.A., Dunne W.M., Ritchie D.J. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012, 34:1314-1323.
60. Livermore D.M., Warner M., Mushtaq S., Doumith M., Zhang J., Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011, 37:415-419.
61. Souli M., Galani I., Boukovalas S., Gourgoulis M.G., Chryssouli Z., Kanellakopoulou K., et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011, 55:2395-2397.
62. Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 1990, 18:S65-S69.
63. Zambon Switzerland Ltd Monurol (fosfomycin tromethamine) package insert 2007, St. Louis, MO.
64. Michalopoulos A., Virtzili S., Rafailidis P., Chalevelakis G., Damala M., Falagas M.E. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010, 16:184-186.
65. Roussos N., Karageorgopoulos D.E., Samonis G., Falagas M.E. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009, 34:506-515.
66. Bergan T., Thorsteinsson S.B., Albini E. Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy 1993, 39:297-301.
67. Patel S.S., Balfour J.A., Bryson H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997, 53:637-656.
68. Mazzei T., Cassetta M.I., Fallani S., Arrigucci S., Novelli A. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections. Int J Antimicrob Agents 2006, 28:S35-S41.
69. Lipman J., Udy A.A., Roberts J.A. Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? the antibiotic story. Anaesth Intensive Care 2011, 39:999-1000.
70. Parker S., Lipman J., Koulenti D., Dimopoulos G., Roberts J.A. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013, 42:289-293.
71. Parker S.L., Frantzeskaki F., Wallis S.C., Diakaki C., Giamarellou H., Koulenti D., et al. Population pharmacokinetics of fosfomycin in critically ill patients. Antimicrob Agents Chemother 2015, 59:6471-6476.
72. Joukhadar C., Klein N., Dittrich P., Zeitlinger M., Geppert A., Skhirtladze K., et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003, 51:1247-1252.
73. Frossard M., Joukhadar C., Erovic B.M., Dittrich P., Mrass P.E., Van Houte M., et al. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Antimicrob Agents Chemother 2000, 44:2728-2732.
74. Matzi V., Lindenmann J., Porubsky C., Kugler S.A., Maier A., Dittrich P., et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010, 65:995-998.
75. Miro J.M., Entenza J.M., Del Rio A., Velasco M., Castaneda X., Garcia de la Maria C., et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012, 56:4511-4515.
76. Scaglione F., Cicchetti F., Demartini G., Arcidiacono M. Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt. Int J Clin Pharmacol Res 1994, 14:107-109.
77. Gardiner B.J., Mahony A.A., Ellis A.G., Lawrentschuk N., Bolton D.M., Zeglinski P.T., et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?. Clin Infect Dis 2014, 58:e101-e105.
78. Pfausler B., Spiss H., Dittrich P., Zeitlinger M., Schmutzhard E., Joukhadar C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004, 53:848-852.
79. Sauermann R., Karch R., Langenberger H., Kettenbach J., Mayer-Helm B., Petsch M., et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother 2005, 49:4448-4454.
80. Borsa F., Leroy A., Fillastre J.P., Godin M., Moulin B. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrob Agents Chemother 1988, 32:938-941.
81. Bouchet J.L., Quentin C., Albin H., Vincon G., Guillon J., Martin-Dupont P. Pharmacokinetics of fosfomycin in hemodialyzed patients. Clin Nephrol 1985, 23:218-221.
82. Gattringer R., Meyer B., Heinz G., Guttmann C., Zeitlinger M., Joukhadar C., et al. Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration. J Antimicrob Chemother 2006, 58:367-371.
83. Florent A., Chichmanian R.M., Cua E., Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents 2011, 37:82-83.
84. Sastry S., Clarke L.G., Alrowais H., Querry A.M., Shutt K.A., Doi Y. Clinical appraisal of fosfomycin in the era of antimicrobial resistance. Antimicrob Agents Chemother 2015, 59:7355-7361.
85. Knothe H., Schafer V., Sammann A., Shah P.M. Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection 1991, 19:18-20.
86. Frimodt-Møller N. Fosfomycin. Kucer's the use of antibiotics 2010, 935-944. Hodder Arnold, London. M.L. Grayson, S.M. Crowe, J.S. McCarthy, J. Mills, J.W. Mouton, S.R. Norrby (Eds.).
87. Inouye S., Niizato T., Takeda U., Koeda T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn 1982, 5:659-669.
88. Yoshiyama Y., Yazaki T., Wong P.C., Beauchamp D., Kanke M. The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity in rats. J Infect Chemother 2001, 7:243-246.
89. Kreft B., de Wit C., Marre R., Sack K. Experimental studies on the nephrotoxicity of amphotericin B in rats. J Antimicrob Chemother 1991, 28:271-281.
90. Michalopoulos A.S., Livaditis I.G., Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011, 15:e732-e739.
91. Falagas M.E., Vouloumanou E.K., Togias A.G., Karadima M., Kapaskelis A.M., Rafailidis P.I., et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010, 65:1862-1877.
92. Qiao L.D., Zheng B., Chen S., Yang Y., Zhang K., Guo H.F., et al. Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study. BMJ Open 2013, 3:e004157.
93. Rhodes N.J., Gardiner B.J., Neely M.N., Grayson M.L., Ellis A.G., Lawrentschuk N., et al. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. J Antimicrob Chemother 2015, 70:2068-2073.
94. Ongun S., Aslan G., Avkan-Oguz V. The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate. Urol Int 2012, 89:439-444.
95. Grayson M.L., Macesic N., Trevillyan J., Ellis A.G., Zeglinski P.T., Hewitt N.H., et al. Fosfomycin for treatment of prostatitis: new tricks for old dogs. Clin Infect Dis 2015, 61:1141-1143.
96. Fiadjoe P., Kannan K., Rane A. Maternal urological problems in pregnancy. Eur J Obstet Gynecol Reprod Biol 2010, 152:13-17.
97. Stein G.E. Fosfomycin tromethamine: single-dose treatment of acute cystitis. Int J Fertil Womens Med 1999, 44:104-109.
98. Krcmery S., Hromec J., Demesova D. Treatment of lower urinary tract infection in pregnancy. Int J Antimicrob Agents 2001, 17:279-282.
99. Usta T.A., Dogan O., Ates U., Yucel B., Onar Z., Kaya E. Comparison of single-dose and multiple-dose antibiotics for lower urinary tract infection in pregnancy. Int J Gynaecol Obstet 2011, 114:229-233.
100. Bayrak O., Cimentepe E., Inegol I., Atmaca A.F., Duvan C.I., Koc A., et al. Is single-dose fosfomycin trometamol a good alternative for asymptomatic bacteriuria in the second trimesterof pregnancy?. Int Urogynecol J Pelvic Floor Dysfunct 2007, 18:525-529.
101. Rudenko N., Dorofeyev A. Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study. Arzneimittelforschung 2005, 55:420-427.
102. Falagas M.E., Giannopoulou K.P., Kokolakis G.N., Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008, 46:1069-1077.
103. Legat F.J., Maier A., Dittrich P., Zenahlik P., Kern T., Nuhsbaumer S., et al. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003, 47:371-374.
104. Forestier F., Salvanet-Bouccara A., Leveques D., Junes P., Rakotondrainy C., Dublanchet A., et al. Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Eur J Ophthalmol 1996, 6:137-142.
105. Rosso-Fernandez C., Sojo-Dorado J., Barriga A., Lavin-Alconero L., Palacios Z., Lopez-Hernandez I., et al. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial. BMJ Open 2015, 5:e007363.
106. Wu T.H., Huang F.L., Fu L.S., Chou C.M., Chien Y.L., Huang C.M., et al. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux. J Microbiol Immunol Infect 2014.
107. Xu-hong Y., Falagas M.E., Dong W., Karageorgopoulos D.E., De-feng L., Rui W. In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo) 2014, 67:369-371.
108. Descourouez J.L., Jorgenson M.R., Wergin J.E., Rose W.E. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 2013, 57:1518-1520.
109. Hauser C., Hirzberger L., Unemo M., Furrer H., Endimiani A. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 2015, 59:1605-1611.
110. Santos D.A., Nascimento M.M., Vitali L.H., Martinez R. In vitro activity of antimicrobial combinations against multidrug-resistant Pseudomonas aeruginosa. Rev Soc Bras Med Trop 2013, 46:299-303.
111. Wei W., Yang H., Liu Y., Ye Y., Li J. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother 2015, 1973947815Y0000000030.
112. Montgomery A.B., Rhomberg P.R., Abuan T., Walters K.A., Flamm R.K. Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. Antimicrob Agents Chemother 2014, 58:3708-3713.
113. Tangden T., Hickman R.A., Forsberg P., Lagerback P., Giske C.G., Cars O. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014, 58:1757-1762.
114. Sbrana F., Malacarne P., Viaggi B., Costanzo S., Leonetti P., Leonildi A., et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013, 56:697-700.
115. Kyle J.M., Stollings J.L., White K.D., Noto M.J., Wheeler A.P. Fosfomycin for multidrug treatment of Klebsiella pneumoniae carbapenemase bacteremia. Ann Pharmacother 2015, 49:366-367.
116. Simkins J., Fan J., Camargo J.F., Aragon L., Frederick C. Intravenous fosfomycin treatment for carbapenem-resistant Klebsiella pneumoniae in the United States. Ann Pharmacother 2015, 49:1177-1178.
117. Karageorgopoulos D.E., Miriagou V., Tzouvelekis L.S., Spyridopoulou K., Daikos G.L. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012, 67:2777-2779.
118. del Rio A., Gasch O., Moreno A., Pena C., Cuquet J., Soy D., et al. Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis 2014, 59:1105-1112.